Ozempic
Novo Nordisk Invests $1.1 Billion to Expand GLP-1 Drug Manufacturing in Brazil
Novo Nordisk , GLP-1 production , Brazil investment , Wegovy and Ozempic , Diabetes treatment , Obesity treatment , Montes Claros facility , Pharmaceutical manufacturing
FDA Approves Ozempic for Reducing Kidney Disease Risks in Adults with Type 2 Diabetes and Chronic Kidney Disease
Ozempic, FDA Approval, Type 2 Diabetes, Chronic Kidney Disease (CKD), Kidney Disease Risks, Cardiovascular Disease Risks, Semaglutide, GLP-1 Receptor Agonist
EU Regulator to Investigate Potential Link Between Ozempic and Rare Eye Condition NAION
Ozempic, NAION, European Medicines Agency, Novo Nordisk, semaglutide, eye disorder, diabetes drug, investigation
Novo Nordisk’s Ozempic Expected to Face Medicare Price Negotiations in 2025
Ozempic, Medicare, price negotiations, Novo Nordisk, diabetes medication, Inflation Reduction Act
Federal Trade Commission Challenges Novo Nordisk’s Ozempic and Over 300 ‘Junk’ Patent Listings in FDA Database
FTC, Novo Nordisk, Ozempic, FDA, patent listings, crackdown, junk patents, pharmaceutical industry, intellectual property, drug development.
EU Regulators Confirm No Link Between GLP-1 Drugs and Suicidal Thoughts
GLP-1 drugs, Ozempic, Wegovy, European Medicines Agency (EMA), No link to suicidal thoughts, Investigation
Novo Nordisk Gets 2023 Profit Beat Fueled by Ozempic, Wegovy Sales Spike
Nordisk, Ozempic, Constant – dosing instruction fragment, exchange rate